BioAtla, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
BCAB$1.74-44.7%Stored close · as of Aug 28, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(in thousands)
| Years ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(59,607) | $(69,776) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 373 | 925 |
| Loss on disposal of property and equipment | 185 | — |
| Change in fair value of warrant liability | (295) | (807) |
| Change in fair value of PPAs liability | 406 | — |
| Commitment fee under SEPA | 282 | — |
| Financing costs related to PPAs | 742 | — |
| Stock-based compensation | 5,434 | 8,921 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 1,128 | 2,903 |
| Accounts payable and accrued expenses | 2,804 | (13,461) |
| Right-of-use assets and lease liabilities, net | 344 | (641) |
| Net cash used in operating activities | (48,204) | (71,936) |
| Cash flows from financing activities | ||
| Proceeds from PPAs | 7,125 | — |
| Payment of financing costs related to issuance of common stock, PPAs and SEPA | (897) | — |
| Proceeds from issuance of common stock and warrants, net of issuance costs | — | 9,215 |
| Proceeds from issuance of common stock under Employee Stock Purchase Plan | 100 | 342 |
| Payments for taxes related to net settlement of equity awards | (52) | (46) |
| Net cash provided by financing activities | 6,276 | 9,511 |
| Net decrease in cash and cash equivalents | (41,928) | (62,425) |
| Cash and cash equivalents, beginning of period | 49,046 | 111,471 |
| Cash and cash equivalents, end of period | $7,118 | $49,046 |
| Supplemental disclosure of non-cash investing and financing activities | ||
| Increase in right-of-use assets and operating lease liabilities resulting from contract modification | $5,999 | $— |
| PPAs related costs included in accounts payable and accrued expense | $289 | $— |
| Fair value of common stock issued in satisfaction of PPAs liability | $3,389 | $— |
| Equity issuance costs included in accounts payable and accrued expense | $— | $445 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.